Keqian Biotech (688526.SH): Net profit of 87.228 million yuan in the first quarter decreased 35.64% year-on-year

On April 29, Ge Longhui Biotech (688526.SH) released its first quarter report. Operating revenue was 200 million yuan, down 26.68% year on year, net profit was 87.228 million yuan, down 35.64% year on year, after deducting non-net profit of 76.1578 million yuan, down 40.56% year on year, with basic earnings of 0.18 yuan per share.

Gelonghui Finance15:41

Keqian Biology (688526) First Coverage Report: Product Strength+R&D Strength Building Core Competitiveness of Leading Companies Without Forced Exemption of Pig Seedlings

In the short term, as 24H2 pig prices enter an upward cycle, demand for animal insurance is expected to pick up. Pig prices have continued to be low since 23 years, and the downstream pig farming industry has been in losses for 15 consecutive months. The triple impact of financial pressure, pessimistic expectations, and the epidemic

西部證券14:31

Southwest Securities released a research report on April 11 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) comments: pig vaccines drive revenue growth, and depreciation affects profits; 2) pr

Southwest Securities released a research report on April 11 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) comments: pig vaccines drive revenue growth, and depreciation affects profits; 2) promote technological innovation to build the company's core competitiveness; 3) production capacity on the breeding side continues to decline, and cycle reversal drives volume and price increases in the sports insurance sector. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 11 08:10

SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging

SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging down profit levels; 2) the main pig breeding business is stable, and the poultry seedlings business continues to expand; 3) R&D lays the future, and there are sufficient reserves of new products. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 9 15:54

Keqian Biology (688526): Swine vaccine drives revenue growth, increases impairment and affects profits

Performance summary: The company released its 2023 annual report. In 2023, the company achieved revenue of 1,064 billion yuan, +6.27% year-on-year, and realized net profit to mother of 396 million yuan, -3.32% year-on-year. which

西南證券Apr 9 00:00

Keqian Biotech (688526) 2023 Report Review: Credit impairment dragged down Q4's net profit to mother decreased by about 70% year-on-year

The gross margin of the main business was under pressure, and large credit impairment confirmed that the company's net profit to the mother decreased by 3% year-on-year in 2023. The company achieved revenue of 1,064 billion yuan in 2023, +6.27% year-on-year, mainly due to the company strengthening market development

國信證券Apr 8 19:21